NBOMe & NBOH Psychedelics: 25I-NBOMe, 25E-NBOH, Seizures & Severe Toxicity

NBOMe & NBOH Psychedelics

Quick answer

NBOMe and NBOH compounds are very potent N-benzyl phenethylamine psychedelics that strongly activate serotonin 5-HT2A receptors.

Unlike many classical psychedelic discussions, this family has a substantial record of severe acute toxicity.

What the systematic review found

A systematic review of 20 analytically confirmed NBOMe patients reported frequent agitation, tachycardia and hypertension. Seizures occurred in 40% of the reported patients, intensive-care admission was common and fatalities were reported.

These were selected published toxicity cases, not a population-level incidence estimate.

Severe toxicity pattern

Published cases describe combinations of:

• extreme agitation;
• hallucinations;
• tachycardia and hypertension;
• seizures;
• hyperthermia;
• clonus or serotonergic features;
• rhabdomyolysis;
• metabolic acidosis;
• acute kidney injury;
• death.

Mislabeling is a central risk

NBOMe compounds have historically been sold on blotter and sometimes misrepresented as LSD.

More recently, the NBOH market shows the same problem: an analytically confirmed severe case involved powder labeled “25I-NBOH” that actually contained 25E-NBOH plus MDPHP.

Bottom line

The NBOMe/NBOH family is a strong example of why “psychedelic” does not mean uniformly low physiologic risk. Identity uncertainty and very high receptor potency make this cluster especially important for harm-reduction education.

Related evidence

• 25I-NBOMe
• 25E-NBOH
• RC psychedelics

From chemistry to clinical meaning

For NBOMe & NBOH Psychedelics, chemical similarity to a familiar entactogen or psychedelic can help explain why certain effects are plausible, but similarity is not interchangeability. Metabolism, transporter activity, receptor efficacy, duration, and active metabolites can all change after relatively small structural modifications. Human case reports and analytically confirmed exposures therefore deserve more weight than simple structure-based predictions when discussing real-world safety.

Familiar subjective effects are not a safety test

People often compare NBOMe & NBOH Psychedelics with MDMA, LSD, psilocybin, or another better-known drug because the subjective effects overlap. That comparison can be useful descriptively but should stop there. Similar euphoria, empathy, sensory change, or psychedelic effects do not establish equivalent cardiovascular load, seizure risk, duration, metabolism, or interaction potential.

The same problem applies to online claims that a compound is “cleaner,” “gentler,” or “more functional.” Those terms describe experiences, not validated toxicology endpoints.

The most important safety distinction

A psychologically difficult experience and a medical emergency are not the same thing. Panic, fear, or perceptual distortion may occur without organ toxicity, while seizures, marked hyperthermia, collapse, severe chest pain, persistent loss of consciousness, or dangerous behavioral disorganization require urgent assessment. When the actual product is uncertain, responders should know that a novel or mislabeled substance may be involved.

Polysubstance use can also change the clinical picture dramatically, especially when stimulants, depressants, or additional serotonergic drugs are present.

What better evidence would look like

A stronger evidence base for NBOMe & NBOH Psychedelics would combine verified chemical identity with prospective clinical observation, serial vital signs, comprehensive co-exposure testing, validated analytical concentrations, and follow-up. Controlled pharmacokinetic work could clarify duration and metabolites without needing to infer them from anecdotes.

Until those data exist, uncertainty about purity, concentration, interactions, and uncommon severe outcomes belongs in the conclusion rather than being hidden behind confident user reports.